Biopharmaceutical company
Appears in 3 stories · Last updated Nov 12, 2026
Maker of Hepcludex, the first FDA-approved chronic hepatitis D treatment in the U.S.
On November 8, Vir Biotechnology said a two-drug combination cleared detectable hepatitis D virus and normalized a liver enzyme in 44% of treated patients after 48 weeks. In the 124-patient Phase 3 trial, called ECLIPSE 1, 79% of treated patients had no detectable virus at all.
Updated 3 days ago
As of August 2026: Developer and marketer of Bixlenvo
Roughly 5% of Americans living with HIV take their antiretrovirals as several pills a day, because resistance, side effects, or other medications rule out standard single tablets. On Thursday the FDA approved a pill built for that group.
Updated Aug 27
As of June 2026: Maker of Trodelvy; holds the new first-line approval
Triple-negative breast cancer is aggressive and short on options. On June 24, 2026, the U.S. Food and Drug Administration cleared Gilead Sciences' Trodelvy as a first-line treatment, moving a drug once used only after other therapies failed to the front of the line. Six days earlier, the European Commission had done the same for patients in the EU who are ineligible for immunotherapy.
Updated Jun 25
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
